![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
PRO 140 Single-Agent Maintenance Therapy
for HIV-1 Infection: A 2-Year Update
|
|
|
Reported by Jules Levin
CROI 2017 Feb 14-16 Seattle, WA
Themed Discussion abbreviated slide presentation, poster has more information.
PRO140 Single-Agent Maintenance Therapy for HIV-1 Infection: A 2-Year Update
Kush Dhody
Amarex Clinical Research, LLC, Germantown, MD, USA
http://www.croiwebcasts.org/console/player/33640?mediaType=slideVideo&
PRO 140 Single-Agent Maintenance Therapy for HIV-1 Infection: A 2-Year Update
![CROI1](../images/022817/022817-3/CROI1.gif)
Reported by Jules Levin
CROI 2017 Feb 14-16 Seattle, WA
Jay Lalezari1, Kush Dhody2, Ula Kowalczyk1, Kazem Kazempour2, Nader Pourhassan3 and Paul J. Maddon4
1Quest Clinical Research, San Francisco, CA, 2Amarex Clinical Research, LLC, Germantown, MD 3CytoDyn Inc., Vancouver, WA, 4Maddon Advisors LLC, Scarsdale, NY
![CROI2](../images/022817/022817-3/CROI2.gif)
![CROI3](../images/022817/022817-3/CROI3.gif)
![CROI4](../images/022817/022817-3/CROI4.gif)
![CROI5](../images/022817/022817-3/CROI5.gif)
![CROI6](../images/022817/022817-3/CROI6.gif)
![CROI7](../images/022817/022817-3/CROI7.gif)
![CROI8](../images/022817/022817-3/CROI8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|